Dennis Langer

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Philadelpha, PA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Dennis Langer
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Dennis Langer

Form 4 holding Director

MYRIAD GENETICS INC

Security class
Common Stock
Shares / value
106,802
Estimated value
$2,044,190
Report date
30 Jun 2022
Price
$19.14
Ownership
Direct
Form 4 holding Director

Brooklyn ImmunoTherapeutics, Inc.

Security class
Stock Option
Shares / value
67,000
Estimated value
Report date
08 Dec 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

MYRIAD GENETICS INC

Security class
Non-Qualified Stock Option (right to buy)
Shares / value
30,000
Estimated value
Report date
30 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Form 4 holding Director

Quoin Pharmaceuticals, Ltd.

Security class
Share Option (Right to Buy)
Shares / value
21,709
Estimated value
Report date
04 Feb 2026
Price
Ownership
Direct
Underlying class
ADS
Underlying amount
Form 4 holding Director

Quoin Pharmaceuticals, Ltd.

Security class
Series H Warrants (Right to Buy)
Shares / value
15,152
Estimated value
Report date
14 Oct 2025
Price
Ownership
Direct
Underlying class
ADS
Underlying amount
Form 4 holding Director

Quoin Pharmaceuticals, Ltd.

Security class
Series I Warrants (Right to Buy)
Shares / value
15,152
Estimated value
Report date
14 Oct 2025
Price
Ownership
Direct
Underlying class
ADS
Underlying amount
Form 4 holding Director

Quoin Pharmaceuticals, Ltd.

Security class
Series J Warrants (Right to Buy)
Shares / value
15,152
Estimated value
Report date
14 Oct 2025
Price
Ownership
Direct
Underlying class
ADS
Underlying amount
Form 4 holding Director

Quoin Pharmaceuticals, Ltd.

Security class
Series K Warrants (Right to Buy)
Shares / value
15,152
Estimated value
Report date
14 Oct 2025
Price
Ownership
Direct
Underlying class
ADS
Underlying amount

Insider Reports Filed by Dennis Langer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .